Ipilimumab/nivolumabHypophysitis with panhypopituitarism, central diabetes insipidus and type 1 diabetes mellitus: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1734卷 / 1期

关键词：

D O I：

10.1007/s40278-019-56418-6

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：293 / 293

相关论文

共 50 条

[31] Ipilimumab/nivolumabHypophysitis: case report
Reactions Weekly, 2019, 1748 (1) : 266 - 266
[32] Ipilimumab/nivolumabHypophysitis: case report
Reactions Weekly, 2019, 1747 (1) : 159 - 159
[33] Ipilimumab/nivolumabHypophysitis: case report
Reactions Weekly, 2021, 1847 (1) : 259 - 259
[34] Ipilimumab/nivolumabHypophysitis: case report
Reactions Weekly, 2023, 1954 (1) : 261 - 261
[35] IpilimumabHypophysitis and central diabetes insipidus: case report
Reactions Weekly, 2018, 1714 (1) : 235 - 235
[36] Central (neurogenic) diabetes insipidus: A case report
Larrauri Monterroso, S.
Perez Garay, R.
Martinez Roda, I.
Del Olmo Sedano, J.
Fernandez Da Vila, B.
Jimenez Gonzalez, D.
Lopez Urrutia, A.
CLINICA CHIMICA ACTA, 2019, 493 : S231 - S232
[37] TozinameranTransient central diabetes insipidus: case report
Reactions Weekly, 2024, 2034 (1) : 367 - 367
[38] KetamineTransient central diabetes insipidus: case report
Reactions Weekly, 2017, 1637 (1) : 124 - 124
[39] BetamethasoneUnmasking of central diabetes insipidus: case report
Reactions Weekly, 2022, 1895 (1) : 96 - 96
[40] HydrocortisoneUnmasking of central diabetes insipidus: case report
Reactions Weekly, 2017, 1643 (1) : 144 - 144

← 1 2 3 4 5 →